Edition:
United States

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

17.16USD
12 Dec 2017
Change (% chg)

$0.13 (+0.76%)
Prev Close
$17.03
Open
$17.05
Day's High
$17.41
Day's Low
$17.02
Volume
254,233
Avg. Vol
386,866
52-wk High
$20.76
52-wk Low
$6.75

Latest Key Developments (Source: Significant Developments)

Corcept Therapeutics posts Q3 earnings per share $0.11
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics announces third quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update.Q3 GAAP earnings per share $0.11.Q3 revenue $42.8 million versus I/B/E/S view $42 million.Q3 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $157 million to $162 million.  Full Article

Corcept Therapeutic says Dohmen Life Science Services filed a complaint alleging Corcept unlawfully terminated Dohmen agreement
Wednesday, 30 Aug 2017 09:09am EDT 

Aug 30 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics Inc - On August 7, 2017, Dohmen Life Science Services filed a complaint alleging corcept unlawfully terminated dohmen agreement.Corcept Therapeutics - Dohmen has since informed Corcept that it is withholding cash payments it collects from sale of Korlym that Dohmen is obligated to pay.Corcept Therapeutics Inc - These cash and receivables total approximately $13.2 million..Corcept Therapeutics Inc - Dohmen has stated that it will remit to Corcept any balance in excess of its calculation of such damages..Corcept Therapeutics - On August 29, corcept filed complaint against Dohmen alleging fraudulent inducement, negligent misrepresentation, breach of contract.Corcept Therapeutics - Immediately following Dohmen's cessation of services under agreement, Corcept began serving Korlym patients through another specialty pharmacy.  Full Article

Corcept Therapeutics says entered into distribution services agreement with Optime Care to provide specialty pharmacy services to co- SEC Filing‍​
Monday, 7 Aug 2017 06:01pm EDT 

Aug 7 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics - on Aug 4, co entered into distribution services agreement with Optime Care to provide specialty pharmacy services to co ‍​.Corcept Therapeutics-under terms of agreement Optime will act as exclusive specialty pharmacy distributor of Korlym in us for term of agreement.Corcept Therapeutics says ‍initial term of agreement is 5 yrs from effective date of Aug 4, unless earlier terminated pursuant its terms - SEC filing​.  Full Article

Corcept Therapeutics Q2 GAAP earnings per share $0.10
Tuesday, 1 Aug 2017 04:05pm EDT 

Aug 1 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics announces second quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update.Q2 non-GAAP earnings per share $0.13.Q2 GAAP earnings per share $0.10.Q2 revenue $35.6 million versus I/B/E/S view $32.5 million.Sees FY 2017 revenue $145 million to $155 million.Q2 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.FY2017 revenue view $131.9 million -- Thomson Reuters I/B/E/S.  Full Article

Corcept therapeutics Q1 GAAP earnings per share $0.04
Monday, 1 May 2017 04:05pm EDT 

May 1 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics announces first quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update.Q1 non-GAAP earnings per share $0.06.Q1 GAAP earnings per share $0.04.Q1 revenue $27.6 million versus I/B/E/S view $25.5 million.Sees FY 2017 revenue $125 million to $135 million.Q1 earnings per share view $0.03 -- Thomson Reuters I/B/E/S.FY2017 revenue view $124.0 million -- Thomson Reuters I/B/E/S.  Full Article

Corcept Therapeutics files for mixed shelf of up to $200 mln
Monday, 13 Mar 2017 05:12pm EDT 

Corcept Therapeutics Inc : Files for mixed shelf of up to $200 million - SEC filing . In addition, 349,425 shares of co's common stock offered by the selling stockholders . Co will not receive any proceeds from the sale of co's common stock by the selling stockholders Source: (http://bit.ly/2nxNmIM) Further company coverage: [CORT.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Corcept Therapeutics posts Q4 earnings per share $0.04
Monday, 6 Mar 2017 08:30am EST 

Corcept Therapeutics Inc : Corcept Therapeutics announces fourth quarter and full-year 2016 financial results; increases 2017 revenue guidance . Q4 GAAP earnings per share $0.04 . Q4 revenue $23.8 million versus I/B/E/S view $23.8 million . Q4 earnings per share view $0.04 -- Thomson Reuters I/B/E/S . Sees FY 2017 revenue $120 million to $130 million . Corcept Therapeutics Inc qtrly non GAAP earnings per share $0.06 .Fy2017 revenue view $121.4 million -- Thomson Reuters I/B/E/S.  Full Article

Corcept Therapeutics reiterates FY 2016 revenue guidance
Tuesday, 1 Mar 2016 04:05pm EST 

Corcept Therapeutics:Reiterates Fy 2016 revenue guidance of $76-81 million.FY 2015 revenue of $79 million - Thomson Reuters I/B/E/S.  Full Article

Corcept Therapeutics gives FY 2016 revenue guidance
Thursday, 28 Jan 2016 04:05pm EST 

Corcept Therapeutics:Estimates Fy 2016 revenue will be $76-81 million.  Full Article

BRIEF-Corcept Therapeutics posts Q3 earnings per share $0.11

* Corcept Therapeutics announces third quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update